Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

SGLT2 inhibitors

- PMLiVE

‘Tentative’ US approval for Lilly/Boehringer’s Lantus copy

Full FDA recommendation for insulin is dependent on lawsuit filed by Sanofi

- PMLiVE

How can pharma meet the need for new diabetes drugs in cash-strapped healthcare markets?

Join the Tweetchat on September 25 using hashtag #M3diabetes

- PMLiVE

Sanofi cuts $925m deal for MannKind’s inhaled insulin

French company bolsters diabetes business with Afrezza collaboration

- PMLiVE

Boehringer/Lilly’s Jardiance approved in US

But the FDA wants four post-marketing studies of the SGLT-2 diabetes drug

The Chinese diabetes challenge

Marketing, communications and commercial relationships in China are full of pitfalls for the unwary, but not without great potential 

- PMLiVE

Novartis buys rights to Google’s ‘smart lens’ technology

Pharma company's eye unit Alcon will focus on uses in diabetes and presbyopia

- PMLiVE

FDA to review Sanofi’s Lantus successor

Decision on company’s next generation insulin Toujeo expected early next year

- PMLiVE

Third time lucky as MannKind’s inhaled insulin is approved

US FDA backs new diabetes treatment Afrezza

- PMLiVE

ADA: Novo says switching to Tresiba could reduce NHS costs

Real world data backs insulin’s ability to reduce hypoglycaemia in people with diabetes

- PMLiVE

ADA: Sanofi shifts focus to embrace integration in diabetes

Pascale Witz unveils company's ambitions at ADA conference

- PMLiVE

ADA: Empagliflozin overcomes FDA concerns

Boehringer and Lilly expect decision on diabetes treatment by end of 2014

- PMLiVE

Sanofi and Medtronic to develop drug-device combos in diabetes

Companies tell PMLiVE their new alliance will take an ‘open innovation’ approach

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links